ACE-031 (1mg)

Description

ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the human activin type IIB receptor (ActRIIB) linked to the Fc region of human IgG1. Originally developed by Acceleron Pharma and investigated in clinical trials for Duchenne muscular dystrophy, it serves as a precise research tool for ActRIIB pathway biology.

Why Researchers Select ACE-031

As a soluble decoy receptor, ACE-031 binds and sequesters multiple TGF-β superfamily ligands — including myostatin (GDF-8), activin A, GDF-11, and BMP-9 — preventing engagement with their endogenous receptors. Unlike targeted myostatin antibodies, ACE-031 captures the full ActRIIB ligand landscape, allowing researchers to assess the combined contribution of multiple TGF-β pathway members to specific phenotypes in muscle wasting, bone density, and fibrosis models.

Common Research Applications

• Myostatin pathway inhibition in skeletal muscle models
• Muscle wasting (cachexia, sarcopenia) pathway research
• Bone density and osteoblast/osteoclast balance studies
• Activin A-driven fibrosis pathway investigation
• Broad TGF-β superfamily ligand neutralization studies

Molecular Profile

• Type: Recombinant ActRIIB-Fc fusion protein
• Ligands neutralized: Myostatin, Activin A, GDF-11, BMP-9
• Form: Lyophilized | Purity: ≥95% (SDS-PAGE + HPLC)

Storage: −20°C or below long-term. Aliquot before freezing; avoid repeated freeze-thaw cycles.

For Research Use Only. Not for human or veterinary use.